


Figure S1. Flow chart of patient inclusion and exclusion.



*Multiple selection of patients possible.

Abbreviations:

GSR-ET: German Stroke Registry-Endovascular Treatment; ICA: Internal Carotid Artery; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; END: early neurological deterioration tPA: tissue plasminogen activator

Table S1. Patients' baseline, procedural and outcome characteristics stratified by functional outcome at 90 days

	Total N=817	mRS≤1 N=425	mRS ≥2 N=392	P- value
Baseline patient characteristics				
Age	72 (62-80)	68 (58-77)	77 (67-83)	<0.001
Male sex	419 (51%)	240 (56%)	179 (46%)	0.002
Prestroke mRS	0 (0-0)	0 (0-0)	0 (0-1)	<0.001
NIHSS at admission	4 (2-5)	3 (2-5)	4 (2-5)	<0.001
Hypertension	611 (75%)	302 (71%)	309 (79%)	0.011
Diabetes mellitus	171 (21%)	71 (17%)	100 (26%)	0.002
Dyslipidemia	369 (45%)	176 (42%)	193 (49%)	0.022
Atrial fibrillation	286 (35%)	129 (30%)	157 (40%)	0.003
Time from symptom onset/last seen well to admission (min)	180 (80-379)	164 (73-328)	207 (96-452)	0.001
Imaging characteristics				
ASPECTS	9 (8-10)	9 (8-10)	9 (8-10)	0.12
Left hemispheric stroke	446 (55%)	230 (54%)	216 (55%)	0.78
Intracranial ICA	99 (12%)	49 (12%)	50 (13%)	0.59
M1	375 (46%)	194 (46%)	160 (41%)	0.16
M2	402 (49%)	182 (43%)	182 (46%)	0.30
Treatment characteristics				
Administration of tPA	334 (41%)	202 (48%)	132 (34%)	<0.001
Time from admission to groin puncture (min)	81 (55-122)	82 (57-117)	79 (50-128)	0.77
General anesthesia	522 (66%)	254 (61%)	268 (71%)	0.004
No. of passes	1 (1-3)	1 (1-3)	2 (1-3)	0.11
TICI 0	55 (7%)	14 (3%)	41 (10%)	<0.001
TICI 1	20 (2%)	4 (1%)	16 (4%)	0.004
TICI 2a	39 (5%)	12 (3%)	27 (7%)	0.006
TICI 2b	268 (33%)	153 (36%)	115 (29%)	0.043
TICI 3	435 (53%)	242 (57%)	193 (49%)	0.027
Successful recanalization [TICI 2b-3]	703 (86%)	395 (93%)	308 (79%)	<0.001
Adverse event during treatment	147 (18%)	72 (17%)	75 (19%)	0.41
Vasospasm	42 (5%)	29 (7%)	13 (3%)	0.023
Clot migration and embolization	28 (3%)	12 (3%)	16 (4%)	0.32
Dissection or perforation	27 (3%)	11 (3%)	16 (4%)	0.23
Follow-up characteristics				
24-hour NIHSS	3 (1-6)	2 (0-3)	5 (2-12)	<0.001
END	192 (24%)	38 (9%)	154 (39%)	<0.001
Groin hematoma after 24 hours	12 (1%)	4 (1%)	8 (2%)	0.19
ICH after 24 hours	72 (9%)	27 (6%)	45 (11%)	0.010
Symptomatic ICH after 24 hours	33 (4%)	3 (1%)	30 (7.7%)	< 0.001
Recurrent Stroke	35 (4%)	13 (3%)	22 (6%)	0.072

Data are presented as median (IQR) for continuous measures, and n (%) for categorical measures. Characteristics were compared by using either Mann-Whitney U test (1) for continuous variables or a chi-square test (2) for categorical variables. Statistical significance: $p < 0.05$.

Abbreviations: END: early neurological deterioration; NIHSS: National Institutes of Health Stroke Scale; ICA: Internal Carotid Artery; ASPECTS: Alberta Stroke Program Early CT score; tPA: tissue plasminogen activator; TICI: Thrombolysis in Cerebral Infarction; mRS: modified Rankin Scale score at 90 days follow-up

Table S2. Coinvestigators: German Stroke Registry Endovascular Treatment (GSR-ET)

Name	Location	Role	Contribution
Dr. med. Anna Alegiani	Asklepios Klinik Altona	Site Investigator	Coordination
Prof. Dr. med. Jörg Berrouschot	Klinikum Altenburger Land	Site Investigator	Coordination
PD Dr. med. Tobias Boeckh-Behrens	Klinikum rechts der Isar der Technischen Universität München	Site Investigator	Coordination
Dr.med. Georg Bohner	Charité Berlin	Site Investigator	Coordination
Prof. Dr. med. Jan Borggrefe	Johannes Wesling Klinikum Minden	Site Investigator	Coordination
Dr. med. Albrecht Bormann	Klinikum Altenburger Land	Site Investigator	Coordination
Dr. med. Michael Braun	Bezirkskrankenhaus Günzburg	Site Investigator	Coordination
Prof. Dr. med. Franziska Dorn	Universitätsklinikum Bonn	Site Investigator	Coordination
Prof. Dr. med. Bernd Eckert	Asklepios Hamburg Altona	Site Investigator	Coordination
Prof. Dr. med. Ulrike Ernemann	Universitätsklinik Tübingen	Site Investigator	Coordination
PD Dr. med. Marielle Ernst	Georg-August-Universität Göttingen	Site Investigator	Coordination
Prof. Dr. med. Jens Fiehler	UKE Hamburg-Eppendorf	Site Investigator	Coordination
Prof. Dr. med. Christian Gerloff	UKE Hamburg-Eppendorf	Site Investigator	Coordination
Prof. Dr. med. Klaus Gröschel	Uniklinik Mainz	Site Investigator	Coordination
Prof. Dr. med. Gerhard F. Hamann	Bezirkskrankenhaus Günzburg	Site Investigator	Coordination
Dr. med. Jörg Hattingen	Klinikum Nordstadt	Site Investigator	Coordination
Dr. med. Karl-Heinz Henn	Klinikum Offenbach	Site Investigator	Coordination
Dr. med. Fee Keil	Uniklinik Frankfurt/Main	Site Investigator	Coordination
Prof. Dr. med. Lars Kellert	LMU Klinikum	Site Investigator	Coordination
Dr. med. Christoffer Kraemer	Klinikum Lüneburg	Site Investigator	Coordination
PD Dr. med. Ruben Mühl-Benninghaus	Klinikum Lüneburg	Site Investigator	Coordination
Prof. Dr. med. Jan Liman	Georg-August-Universität Göttingen	Site Investigator	Coordination
Dr. med. Alexander Ludolph	Klinikum Offenbach	Site Investigator	Coordination
Prof. Dr. med. Christian Nolte	Charité Berlin	Site Investigator	Coordination
Prof. Dr. med. Omid Nikoubashman	Uniklinik RWTH Aachen	Site Investigator	Coordination
Dr. med. Martina Petersen	Klinikum Osnabrück	Site Investigator	Coordination
Prof. Dr. med. Gabor Petzold	Universitätsklinikum Bonn	Site Investigator	Coordination
PD Dr. med. Sven Poli	Universitätsklinik Tübingen	Site Investigator	Coordination
PD Dr. med. Arno Reich	Uniklinik RWTH Aachen	Site Investigator	Coordination
Prof. Dr. med. Joachim Röther	Asklepios Hamburg Altona	Site Investigator	Coordination
Dr. med. Jan Hendrik Schäfer	Uniklinik Frankfurt/Main	Site Investigator	Coordination
Maximilian Schell	UKE Hamburg-Eppendorf	Site Investigator	Coordination
Prof. Dr. med. Peter Schellinger	Johannes Wesling Klinikum Minden	Site Investigator	Coordination
PD Dr. med Eberhard Siebert	Charité Berlin	Site Investigator	Coordination
Prof. Dr. med. Florian Stögbauer	Klinikum Osnabrück	Site Investigator	Coordination
Prof. Dr. med. Götz Thomalla	UKE Hamburg-Eppendorf	Site Investigator	Coordination
Dr. med. Steffen Tiedt	LMU Klinikum	Site Investigator	Coordination
Prof. Dr. med. Christoph Trumm	LMU Klinikum	Site Investigator	Coordination
Dr. med. Timo Uphaus	Uniklinik Mainz	Site Investigator	Coordination
Dr. med. Silke Wunderlich	Klinikum rechts der Isar der Technischen Universität München	Site Investigator	Coordination
Dr. med. Sarah Zweynert	Charité Berlin	Site Investigator	Coordination